Published in Clin Infect Dis on August 01, 2010
Escherichia coli sequence type ST131 as the major cause of serious multidrug-resistant E. coli infections in the United States. Clin Infect Dis (2010) 4.98
Broad-specificity efflux pumps and their role in multidrug resistance of Gram-negative bacteria. FEMS Microbiol Rev (2011) 2.46
The challenge of efflux-mediated antibiotic resistance in Gram-negative bacteria. Clin Microbiol Rev (2015) 1.81
Intensity and Mechanisms of Fluoroquinolone Resistance within the H30 and H30Rx Subclones of Escherichia coli Sequence Type 131 Compared with Other Fluoroquinolone-Resistant E. coli. Antimicrob Agents Chemother (2015) 1.07
Role of the water-metal ion bridge in mediating interactions between quinolones and Escherichia coli topoisomerase IV. Biochemistry (2014) 0.85
Risk factors for ambulatory urinary tract infections caused by high-MIC fluoroquinolone-susceptible Escherichia coli in women: results from a large case-control study. J Antimicrob Chemother (2015) 0.83
Prevalence and risk factors for quinolone resistance among Escherichia coli strains isolated from males with community febrile urinary tract infection. Eur J Clin Microbiol Infect Dis (2011) 0.83
Modulation of Bacterial Multidrug Resistance Efflux Pumps of the Major Facilitator Superfamily. Int J Bacteriol (2015) 0.83
The effect of a hospital-wide urine culture screening intervention on the incidence of extended-spectrum β-lactamase-producing Escherichia coli and Klebsiella species. Infect Control Hosp Epidemiol (2013) 0.79
Ciprofloxacin Resistance in Enterococcus faecalis Strains Isolated From Male Patients With Complicated Urinary Tract Infection. Korean J Urol (2013) 0.78
Bacillus anthracis GrlAV96A topoisomerase IV, a quinolone resistance mutation that does not affect the water-metal ion bridge. Antimicrob Agents Chemother (2014) 0.77
Defining relatedness in studies of transmission of antimicrobial-resistant organisms: variability in definitions across studies and impact of different approaches on study conclusions. Infect Control Hosp Epidemiol (2012) 0.75
Activity of quinolone CP-115,955 against bacterial and human type II topoisomerases is mediated by different interactions. Biochemistry (2015) 0.75
Contribution of target alteration, protection and efflux pump in achieving high ciprofloxacin resistance in Enterobacteriaceae. AMB Express (2016) 0.75
High fluoroquinolone MIC is associated with fluoroquinolone treatment failure in urinary tract infections caused by fluoroquinolone susceptible Escherichia coli. Ann Clin Microbiol Antimicrob (2017) 0.75
AcrAB efflux pump plays a major role in the antibiotic resistance phenotype of Escherichia coli multiple-antibiotic-resistance (Mar) mutants. J Bacteriol (1996) 8.50
Resolution of recent evolutionary divergence among Escherichia coli from related lineages: the application of pulsed field electrophoresis to molecular epidemiology. J Infect Dis (1990) 8.33
Rapid pulsed-field gel electrophoresis protocol for typing of Escherichia coli O157:H7 and other gram-negative organisms in 1 day. J Clin Microbiol (1997) 5.62
Comparison of the E Test to agar dilution, broth microdilution, and agar diffusion susceptibility testing techniques by using a special challenge set of bacteria. J Clin Microbiol (1991) 4.79
Contributions of individual mechanisms to fluoroquinolone resistance in 36 Escherichia coli strains isolated from humans and animals. Antimicrob Agents Chemother (1996) 4.15
Antibiotic resistance among gram-negative bacilli in US intensive care units: implications for fluoroquinolone use. JAMA (2003) 4.09
Role of the acrAB locus in organic solvent tolerance mediated by expression of marA, soxS, or robA in Escherichia coli. J Bacteriol (1997) 3.81
Genetic characterization of highly fluoroquinolone-resistant clinical Escherichia coli strains from China: role of acrR mutations. Antimicrob Agents Chemother (2001) 3.62
New uses for new and old quinolones and the challenge of resistance. Clin Infect Dis (2000) 3.45
Efflux-mediated resistance to fluoroquinolones in gram-negative bacteria. Antimicrob Agents Chemother (2000) 3.22
Mutation rate and evolution of fluoroquinolone resistance in Escherichia coli isolates from patients with urinary tract infections. Antimicrob Agents Chemother (2003) 3.00
Fluoroquinolone prescribing in the United States: 1995 to 2002. Am J Med (2005) 2.83
Evaluation of VITEK 2 rapid identification and susceptibility testing system against gram-negative clinical isolates. J Clin Microbiol (2001) 2.57
Ineffectiveness of topoisomerase mutations in mediating clinically significant fluoroquinolone resistance in Escherichia coli in the absence of the AcrAB efflux pump. Antimicrob Agents Chemother (2000) 2.40
Phenotypic and genotypic characterization of fecal Escherichia coli isolates with decreased susceptibility to fluoroquinolones: results from a large hospital-based surveillance initiative. J Infect Dis (2006) 1.96
Test characteristics of perirectal and rectal swab compared to stool sample for detection of fluoroquinolone-resistant Escherichia coli in the gastrointestinal tract. Antimicrob Agents Chemother (2005) 1.93
Longitudinal trends in fluoroquinolone resistance among Enterobacteriaceae isolates from inpatients and outpatients, 1989-2000: differences in the emergence and epidemiology of resistance across organisms. Clin Infect Dis (2004) 1.83
Association of organic solvent tolerance and fluoroquinolone resistance in clinical isolates of Escherichia coli. J Antimicrob Chemother (1998) 1.47
Mechanisms involved in the development of resistance to fluoroquinolones in Escherichia coli isolates. J Antimicrob Chemother (1999) 1.39
Emergence of reduced susceptibility and resistance to fluoroquinolones in Escherichia coli in Taiwan and contributions of distinct selective pressures. Antimicrob Agents Chemother (2001) 1.38
Association between fluoroquinolone resistance and mortality in Escherichia coli and Klebsiella pneumoniae infections: the role of inadequate empirical antimicrobial therapy. Clin Infect Dis (2005) 1.35
Characterization of clinical isolates of Escherichia coli showing high levels of fluoroquinolone resistance. J Clin Microbiol (1996) 1.29
Epidemiological interpretation of chromosomal macro-restriction fragment patterns analyzed by pulsed-field gel electrophoresis. J Clin Microbiol (1997) 1.22
The role of patient-to-patient transmission in the acquisition of imipenem-resistant Pseudomonas aeruginosa colonization in the intensive care unit. J Infect Dis (2009) 1.21
Impact of diversity of colonizing strains on strategies for sampling Escherichia coli from fecal specimens. J Clin Microbiol (2008) 1.19
Development of a rapid assay for detecting gyrA mutations in Escherichia coli and determination of incidence of gyrA mutations in clinical strains isolated from patients with complicated urinary tract infections. J Clin Microbiol (1997) 1.19
Molecular analysis of fluoroquinolone-resistance in Escherichia coli on the aspect of gyrase and multiple antibiotic resistance (mar) genes. Yonsei Med J (1998) 1.12
High prevalence of nalidixic acid resistant, ciprofloxacin susceptible phenotype among clinical isolates of Escherichia coli and other Enterobacteriaceae. Diagn Microbiol Infect Dis (2002) 1.08
Colonization and infection with fluoroquinolone-resistant Escherichia coli among cancer patients: clonal analysis. Infection (1999) 1.04
Risk factors for fecal colonization with multiple distinct strains of Escherichia coli among long-term care facility residents. Infect Control Hosp Epidemiol (2009) 1.02
The Garrod lecture. Progress in understanding urinary infections. J Antimicrob Chemother (1991) 0.98
Antimicrobial resistance in gram-negative pathogens: crafting the tools necessary to navigate the long ascent out of the abyss. J Infect Dis (2009) 0.93
Role of computerized physician order entry systems in facilitating medication errors. JAMA (2005) 26.32
Infectious Diseases Society of America and the Society for Healthcare Epidemiology of America guidelines for developing an institutional program to enhance antimicrobial stewardship. Clin Infect Dis (2006) 14.63
Use of florbetapir-PET for imaging beta-amyloid pathology. JAMA (2011) 6.92
Validation studies of the health improvement network (THIN) database for pharmacoepidemiology research. Pharmacoepidemiol Drug Saf (2007) 5.93
Risk of bladder cancer among diabetic patients treated with pioglitazone: interim report of a longitudinal cohort study. Diabetes Care (2011) 5.63
Absence of cross-reactivity between sulfonamide antibiotics and sulfonamide nonantibiotics. N Engl J Med (2003) 5.09
Clinical and microbiological outcomes of serious infections with multidrug-resistant gram-negative organisms treated with tigecycline. Clin Infect Dis (2008) 3.56
SHEA guideline for management of healthcare workers who are infected with hepatitis B virus, hepatitis C virus, and/or human immunodeficiency virus. Infect Control Hosp Epidemiol (2010) 3.44
The relationship between time since registration and measured incidence rates in the General Practice Research Database. Pharmacoepidemiol Drug Saf (2005) 3.24
Systematic review and cost analysis comparing use of chlorhexidine with use of iodine for preoperative skin antisepsis to prevent surgical site infection. Infect Control Hosp Epidemiol (2010) 3.08
Fluoroquinolone utilization in the emergency departments of academic medical centers: prevalence of, and risk factors for, inappropriate use. Arch Intern Med (2003) 3.06
Point: developing a curriculum in clinical pathology. Clin Chem (2006) 2.92
Risk factors and clinical impact of Klebsiella pneumoniae carbapenemase-producing K. pneumoniae. Infect Control Hosp Epidemiol (2009) 2.73
A cluster randomized trial of decision support strategies for reducing antibiotic use in acute bronchitis. JAMA Intern Med (2013) 2.70
Facial emotion recognition in schizophrenia: intensity effects and error pattern. Am J Psychiatry (2003) 2.69
A cognitive neuroscience-based computerized battery for efficient measurement of individual differences: standardization and initial construct validation. J Neurosci Methods (2009) 2.55
Age group and sex differences in performance on a computerized neurocognitive battery in children age 8-21. Neuropsychology (2012) 2.54
Retrospective drug utilization review, prescribing errors, and clinical outcomes. JAMA (2003) 2.51
The impact of emergency department crowding measures on time to antibiotics for patients with community-acquired pneumonia. Ann Emerg Med (2007) 2.51
Mesenchymal stem cells: a new strategy for immunosuppression and tissue repair. Cell Res (2010) 2.46
Cardiac arrest and ventricular arrhythmia in patients taking antipsychotic drugs: cohort study using administrative data. BMJ (2002) 2.46
Hospitalization and mortality rates from peptic ulcer disease and GI bleeding in the 1990s: relationship to sales of nonsteroidal anti-inflammatory drugs and acid suppression medications. Am J Gastroenterol (2002) 2.39
Differences in the epidemiological characteristics and clinical outcomes of pandemic (H1N1) 2009 influenza, compared with seasonal influenza. Infect Control Hosp Epidemiol (2010) 2.29
Antiretroviral medication errors remain high but are quickly corrected among hospitalized HIV-infected adults. Clin Infect Dis (2012) 2.24
Access to emergency care in the United States. Ann Emerg Med (2009) 2.19
Availability of rapid human immunodeficiency virus testing in academic emergency departments. Acad Emerg Med (2008) 2.17
Managed problem solving for antiretroviral therapy adherence: a randomized trial. JAMA Intern Med (2013) 2.16
Validity and completeness of the General Practice Research Database for studies of inflammatory bowel disease. Pharmacoepidemiol Drug Saf (2002) 2.12
Differences in facial expressions of four universal emotions. Psychiatry Res (2004) 2.11
Healthcare utilization and cost of pneumococcal disease in the United States. Vaccine (2011) 2.03
Detection of proximal adenomatous polyps with screening sigmoidoscopy: a systematic review and meta-analysis of screening colonoscopy. Arch Intern Med (2003) 2.02
Comparing different measures of retention in outpatient HIV care. AIDS (2012) 1.98
Phenotypic and genotypic characterization of fecal Escherichia coli isolates with decreased susceptibility to fluoroquinolones: results from a large hospital-based surveillance initiative. J Infect Dis (2006) 1.96
Test characteristics of perirectal and rectal swab compared to stool sample for detection of fluoroquinolone-resistant Escherichia coli in the gastrointestinal tract. Antimicrob Agents Chemother (2005) 1.93
The association between emergency department crowding and hospital performance on antibiotic timing for pneumonia and percutaneous intervention for myocardial infarction. Acad Emerg Med (2006) 1.90
Educational interventions to improve antibiotic use in the community: report from the International Forum on Antibiotic Resistance (IFAR) colloquium, 2002. Lancet Infect Dis (2004) 1.89
Risk factors for fluconazole-resistant Candida glabrata bloodstream infections. Arch Intern Med (2009) 1.86
Surveillance cultures for detection of methicillin-resistant Staphylococcus aureus: diagnostic yield of anatomic sites and comparison of provider- and patient-collected samples. Infect Control Hosp Epidemiol (2009) 1.85
Cardiovascular events and death in children exposed and unexposed to ADHD agents. Pediatrics (2011) 1.84
Longitudinal trends in fluoroquinolone resistance among Enterobacteriaceae isolates from inpatients and outpatients, 1989-2000: differences in the emergence and epidemiology of resistance across organisms. Clin Infect Dis (2004) 1.83
Antibiotic treatment of acute respiratory infections in acute care settings. Acad Emerg Med (2006) 1.82
Impact of inadequate initial antimicrobial therapy on mortality in infections due to extended-spectrum beta-lactamase-producing enterobacteriaceae: variability by site of infection. Arch Intern Med (2005) 1.82
The influence of patient adherence on anticoagulation control with warfarin: results from the International Normalized Ratio Adherence and Genetics (IN-RANGE) Study. Arch Intern Med (2007) 1.79
Validation of diagnostic codes for outpatient-originating sudden cardiac death and ventricular arrhythmia in Medicaid and Medicare claims data. Pharmacoepidemiol Drug Saf (2010) 1.78
Quality of care indicators for gout management. Arthritis Rheum (2004) 1.77
Imipenem resistance among pseudomonas aeruginosa isolates: risk factors for infection and impact of resistance on clinical and economic outcomes. Infect Control Hosp Epidemiol (2006) 1.76
Surveillance for second primary colorectal cancer after adjuvant chemotherapy: an analysis of Intergroup 0089. Ann Intern Med (2002) 1.75
Burden of general medical conditions among individuals with bipolar disorder. Bipolar Disord (2004) 1.74
Racial/ethnic differences in surgical outcomes in veterans following knee or hip arthroplasty. Arthritis Rheum (2005) 1.72
Longitudinal trends in antimicrobial susceptibilities across long-term-care facilities: emergence of fluoroquinolone resistance. Infect Control Hosp Epidemiol (2005) 1.71
Telling truth from lie in individual subjects with fast event-related fMRI. Hum Brain Mapp (2005) 1.70
Sequence-based identification of aerobic actinomycetes. J Clin Microbiol (2004) 1.70
Sex differences in temporo-limbic and frontal brain volumes of healthy adults. Cereb Cortex (2002) 1.69
Association between longer therapy with thiazolidinediones and risk of bladder cancer: a cohort study. J Natl Cancer Inst (2012) 1.69
Quality of Medicaid and Medicare data obtained through Centers for Medicare and Medicaid Services (CMS). Med Care (2007) 1.66
Limbic activation associated with misidentification of fearful faces and flat affect in schizophrenia. Arch Gen Psychiatry (2007) 1.65
Flat affect in schizophrenia: relation to emotion processing and neurocognitive measures. Schizophr Bull (2006) 1.64
Antidepressants and the risk of sudden cardiac death and ventricular arrhythmia. Pharmacoepidemiol Drug Saf (2011) 1.63
Reemergence of gram-negative health care-associated bloodstream infections. Arch Intern Med (2006) 1.63
Asaia bogorensis peritonitis identified by 16S ribosomal RNA sequence analysis in a patient receiving peritoneal dialysis. Am J Kidney Dis (2004) 1.58
Long-term effects of culture of preimplantation mouse embryos on behavior. Proc Natl Acad Sci U S A (2004) 1.57
Antidepressant-warfarin interaction and associated gastrointestinal bleeding risk in a case-control study. PLoS One (2011) 1.54
Changes in veterans' use of outpatient care from 1992 to 2000. Am J Public Health (2005) 1.52
Comparison of Campylobacter jejuni isolates implicated in Guillain-Barré syndrome and strains that cause enteritis by a DNA microarray. Infect Immun (2004) 1.50
Sustained viral suppression in HIV-infected patients receiving antiretroviral therapy. JAMA (2012) 1.48
Fluoroquinolone-resistant Pseudomonas aeruginosa: assessment of risk factors and clinical impact. Am J Med (2006) 1.47
Reduced antibiotic prescribing for acute respiratory infections in adults and children. Br J Gen Pract (2009) 1.46
Risk factors for disseminated candidiasis in children with candidemia. Pediatr Infect Dis J (2004) 1.45
Identification of optimal combinations for empirical dual antimicrobial therapy of Pseudomonas aeruginosa infection: potential role of a Combination Antibiogram. Infect Control Hosp Epidemiol (2006) 1.45
Comparison of prior authorization and prospective audit with feedback for antimicrobial stewardship. Infect Control Hosp Epidemiol (2014) 1.45
Provider inaccuracy in assessing adherence and outcomes with newly initiated antiretroviral therapy. AIDS (2002) 1.44
Represcription of penicillin after allergic-like events. J Allergy Clin Immunol (2004) 1.44
Evaluation of mannitol salt agar, CHROMagar Staph aureus and CHROMagar MRSA for detection of meticillin-resistant Staphylococcus aureus from nasal swab specimens. J Med Microbiol (2007) 1.44
Methylphenidate and risk of serious cardiovascular events in adults. Am J Psychiatry (2012) 1.42
Comparison of unit-specific and hospital-wide antibiograms: potential implications for selection of empirical antimicrobial therapy. Infect Control Hosp Epidemiol (2006) 1.42
The surgery clerkship: an opportunity for preclinical credentialing in urinary catheterization. Am J Surg (2012) 1.40
Campylobacter jejuni cst-II polymorphisms and association with development of Guillain-Barré syndrome. Neurology (2007) 1.40